Eli Lilly (LLY) Short term Debt (2009 - 2026)

Eli Lilly has reported Short term Debt for 18 years, with the latest figure at $4.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt changed 0.41% year-over-year to $4.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.0 billion (changed 0.41% YoY), and the FY2025 full-year result was $1.6 billion, down 68.05% from the prior year.
• Short term Debt for Q1 2026 stood at $4.0 billion, up from $1.6 billion in the prior quarter.
• The five-year high for Short term Debt was $6.9 billion in Q4 2023, with the low at $3.1 million in Q1 2023.
• Historically, Short term Debt has averaged $2.8 billion across 5 years, with a median of $2.1 billion in 2024.
• Annual changes were most pronounced in 2023 — Short term Debt slumped 99.77% — and 2024, when it surged 53174.19%.
• Eli Lilly's Short term Debt stood at $1.5 billion in 2022, then surged by 359.96% to $6.9 billion in 2023, then decreased by 25.89% to $5.1 billion in 2024, then tumbled by 68.05% to $1.6 billion in 2025, then soared by 144.65% to $4.0 billion in 2026.
• The last three Short term Debt figures came in at $4.0 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.